[1]李鹏飞 段 戡 邹旨龙.从健脾益肾法论治骨肉瘤[J].大众科技,2018,20(11):41-43.
　Treatment of Osteosarcoma from Invigorating Spleen and Tonifying Kidney[J].Popular Science & Technology,2018,20(11):41-43.
点击复制

从健脾益肾法论治骨肉瘤()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
20
期数:
2018年11期
页码:
41-43
栏目:
医药与卫生
出版日期:
2018-11-20

文章信息/Info

Title:
Treatment of Osteosarcoma from Invigorating Spleen and Tonifying Kidney
作者:
李鹏飞1 段 戡2 邹旨龙2
（1.广西中医药大学第一临床医学院，广西 南宁 530001； 2.广西中医药大学第一附属医院，广西 南宁 530023）
关键词:
骨肉瘤; 中医药; 健脾益肾
Keywords:
osteosarcoma;  TCM;  invigorating spleen and tonifying kidney
文献标志码:
A
摘要:
通过临床实践以及查阅相关典籍发现：骨肉瘤是由机体正气不足，复感六淫外邪，致阴阳失衡，脏腑功能失调，痰湿瘀浊凝聚而为病，脾肾失衡贯穿骨肉瘤发生、发展的全过程。因此，骨肉瘤的治疗应重视健脾益肾。文章浅析以健脾益肾法治疗骨肉瘤的临床意义，为中医治疗骨肉瘤提供理论基础。
Abstract:
Through clinical practice and consulting the relevant authoritative literatures, it is found that osteosarcoma is caused by the insufficiency of the body’s positive gas, the infection of six exogenous pathogenic factors, which results the imbalance of Yin and Yang, the dysfunction of the viscera and the coagulation of the phlegm, and results the imbalance of spleen and kidney in a whole process of the occurrence and development of osteosarcoma. Therefore, it should be pay attention to invigorating the spleen and benefiting the kidney in the treatment of osteosarcoma. In this paper, the clinical significance of invigorating spleen and tonifying kidney in treating osteosarcoma is discussed, so as to provide theoretical basis for TCM (traditional Chinese medicine) treatment of osteosarcoma.

参考文献/References:

【参考文献】 [1] Li Y,Guo W,Liu S,et al.Silencing transmembrane protein 45B (TNEM45B) inhibits proliferation,invasion,and tumorigenesis in osteosarcoma cells[J].Oncology Research Featuring Preclinical & Clinical Cancer Therapeutics,2017, 25(6):1021-1026. [2] Li X,Yang Z,Han W,et al.Fangchinoline suppresses the proliferation,invasion and tumorigenesis of human osteosarcoma cells through the inhibition of PI3K and downstream signaling pathways[J].Int J Mol Med,2017,40 (2):311-318. [3] 柴丽,董良仓.两种方案对治疗高分化骨肉瘤患者的 5 年无瘤生存率分析[J].检验医学与临床,2013,10:1138-1140. [4] Liu J A,Wang S A B,Zhang Y A,et al.Traditional Chinese medicine and cancer:History,present situation,and development [J].Thoracic Cancer,2015,6(5):561-569. [5] Brown H K,Tellezgabriel M,Heymann D.Cancer stem cells in osteosarcoma[J].Cancer Letters,2017,386:189-195. [6] Zhang W,Han S,Sun K.Combined analysis of gene expression, miRNA expression and DNA methylation profiles of osteosarcoma.[J].Oncology Reports,2017,37(2):1175-1181. [7] Jones K B,Salah Z,Del S M,et al.miRNA signatures associate with pathogenesis and progression of osteosarcoma[J]. Cancer Research,2012,72(7):1865-1877. [8] Chang L,Shrestha S,Lachaud G,et al.Review of microRNA in osteosarcoma and chondrosarcoma[J].Medical Oncology, 2015,32(6):1-7. [9] 易生辉,秦刚,黄肖华,等.骨肉瘤的治疗进展[J].医学综述, 2017,19(8):1529-1532. [10] 丁聚贤,谢兴文,许伟,等.中医药在骨肉瘤放化疗中的作用研究进展[J].中医正骨,2018,30(5):43-49. [11] 王辉,孙桂芝.治疗骨肉瘤经验,世界中医药[J].2012,7(1): 21-22. [12] 程纬民,曾清.补脾肾化瘀毒法联合化疗治疗多发性骨髓瘤溶骨病变20 例临床观察[J].辽宁中医杂志,2009,36(12): 2093-2095. [13] 黄满玉,古建立,李东升,等.恶性骨肿瘤的中医治疗经验浅谈[J].辽宁中医杂志,2011:38(7):1333-1334. [14] 王玉洁,王彦晖,奚胜艳,等.癌症“种子土壤说”新论[J].中华中医药杂志(原中国医药学报),2018,33(3):975-979. [15] 卞胡伟,蒋涛.孟河医派“脾肾相关、活血化瘀”治疗骨质疏松初探[J].江西中医药,2016,47(6):9-11. [16] Foulon S,Brennan B,Gaspar N,et al.Can postoperative radiotherapy be omitted in loc-alised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group[J].Eur J Cancer,2016,61:128-136. [17] 李帅,刘云霞.中医药防治骨肉瘤肺转移的研究进展[J].新中医,2017,49(11):137-141. [18] 李晓伟,杜明昌,曹学伟.扶正法对骨肉瘤生长转移的干预实验研究[J].中华肿瘤防治杂志,2008,15(22):1721- 1723. [19] 张柘,吴剑,郑勇,等.人参皂苷Rg3 抗骨肉瘤LJH-OS 细胞裸鼠移植瘤的作用及其对肿瘤血管生成拟态的影响[J].中华实验外科杂志,2015,32(7):1569-1571. [20] 李瑞芝,马浩清,金晓董,等.加味四君子汤对结肠癌细胞SW620 增殖和凋亡的影响[J].浙江中医杂志,2015,50(7): 487-489. [21] 曹楚楚,黄炉仁,傅芬.PI3K/Akt/mTOＲ信号通路及其相关基因突变与子宫内膜癌靶向性药物治疗的研究进展[J].基础医学与临床2017,37(1):118-122. [22] 郭晓辉,陈志维.肾命学说与骨病治疗的相关性[J].辽宁中医杂志,2013,40(7):1332-1333. [23] 金成辉.基于“脾肾相关”论骨肿瘤的中医治疗[J].环球中医药,2017,10(12):1494-1496. [24] 徐志红.张晓春教授治疗骨转移性癌痛的临床经验总结[D].南京:南京中医药大学,2016. [25] 罗悦琼,李琦.参苓白术散加减治疗肺癌骨转移的疗效及作用机制探讨[J].世界中医药,2016,11(7):1261-1264. [26] Z Wei,X Fang,M Miao.The analysis of the adverse reaction of traditional Chinese medicine tumor bone marrow suppression[J].Materials Science & Engineering Conference Series,2018,301.

相似文献/References:

[1]李瑞祥 陈斯宁.中医药对 COPD 大鼠模型作用机理的研究进展[J].大众科技,2014,16(05):95.
[2]廖咸硕.慢性乙型肝炎中医药治疗进展[J].大众科技,2014,16(10):124.
　Progress in the treatment of chronic hepatitis B with traditional Chinese medicine[J].Popular Science & Technology,2014,16(11):124.
[3]李鹏程 韦艾凌 张永琴 唐秋媛.中医药调控肝癌血管生成的研究近况[J].大众科技,2014,16(11):136.
　Research status on traditional Chinese medicine of angiogenesis inhepatocellular carcinoma[J].Popular Science & Technology,2014,16(11):136.
[4]万 媛.中医药协同治疗卒中后抑郁症的研究近况[J].大众科技,2014,16(12):98.
　The recent clinical research of Chinese-western therapy on post-stroke depression[J].Popular Science & Technology,2014,16(11):98.
[5]杨 赟 梁爱武.中医药对慢性阻塞性肺疾病MMP-9、TIMP-1 影响的研究进展[J].大众科技,2015,15(02):78.
　慢性阻塞性肺疾病；基质金属蛋白酶-9；金属蛋白酶组织抑制-1；气道重塑；中医药[J].Popular Science & Technology,2015,15(11):78.
[6]张艳娟,吴 光.中医药院校助力精准扶贫工作研究——以广西中医药大学定点扶贫为例[J].大众科技,2019,21(09):129.
　Research on Targeted Poverty Alleviation Work in Colleges and Universities of Traditional Chinese Medicine ——Take Guangxi University of Traditional Chinese Medicine as an Example[J].Popular Science & Technology,2019,21(11):129.
[7]陈曹华　李沛桢　周华亮　马潍珩　刘汝专.中医药治疗腰椎间盘突出症术后残留症状的研究进展[J].大众科技,2022,24(06):112.
　Research Status of Postoperative Residual Symptoms of Lumbar Intervertebral Disc Herniation Treated with Traditional Chinese Medicine[J].Popular Science & Technology,2022,24(11):112.
[8]桂雄斌 伏广虎.中医药治疗变应性鼻炎研究进展[J].大众科技,2018,20(06):61.
[9]韦卓 伍燕宏 郑景辉.血府逐瘀汤治疗心血管病的研究进展[J].大众科技,2018,20(06):63.
[10]兰鹏潘凤仙苏锦勋.脑卒中后肩手综合征的中医药外治法研究进展[J].大众科技,2018,20(06):71.

备注/Memo

备注/Memo:
【收稿日期】2018-09-05 【基金项目】广西中医药大学校级一般硕士研究生科研创新项目（YJSP201728）。 【作者简介】李鹏飞（1992－）,男，广西中医药大学第一临床医学院在读硕士研究生，从事中医骨伤科临床研究。 【通信作者】段戡（1964－），男，广西中医药大学第一附属医院仙葫院区关节创伤骨科主任医师，教授，硕士研究生导师，从事骨关节病等方向的教学、研究工作。
更新日期/Last Update: 2018-12-19